Get the Stockscreener App
297.89
0.16%
0.49
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $297.89, with a volume of 2.52M.
It is up +0.16% in the last 24 hours and up +4.95% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$297.40
Open:
$297.72
24h Volume:
2.52M
Relative Volume:
1.14
Market Cap:
$160.37B
Revenue:
$34.76B
Net Income/Loss:
$6.62B
P/E Ratio:
24.37
EPS:
12.223
Net Cash Flow:
$10.61B
1W Performance:
+9.13%
1M Performance:
+4.95%
6M Performance:
-3.86%
1Y Performance:
-6.17%
1-Day Range:
$295.63
$301.54
1-Week Range:
$270.67
$301.66
52-Week Range:
$253.30
$335.88
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
297.89 | 160.11B | 34.76B | 6.62B | 10.61B | 12.22 |
|
LLY
Lilly Eli Co
|
839.87 | 734.96B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
188.64 | 447.90B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
233.91 | 417.90B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
132.39 | 253.54B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
89.19 | 223.58B | 63.43B | 16.42B | 14.72B | 6.4861 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Inc. $AMGN Shares Acquired by O Keefe Stevens Advisory Inc. - MarketBeat
Amgen Inc. $AMGN Shares Sold by Boston Common Asset Management LLC - MarketBeat
Amgen Inc. $AMGN Stock Position Lifted by Talbot Financial LLC - MarketBeat
Ameriflex Group Inc. Cuts Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Ascent Group LLC - MarketBeat
Ameritas Advisory Services LLC Has $1.23 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
How Amgen Inc. (AMGN) Affects Rotational Strategy Timing - news.stocktradersdaily.com
(AMGN) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
(AMGN) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Amgen Inc (AMGN) Ramps Up Manufacturing Capacity in US, Amidst Hefty Tariffs - MSN
Trading the Move, Not the Narrative: (AMGN) Edition - news.stocktradersdaily.com
AMF Tjanstepension AB Grows Stake in Amgen Inc. $AMGN - MarketBeat
4 Reasons to Buy Amgen Stock Right Now - Nasdaq
QRG Capital Management Inc. Increases Position in Amgen Inc. $AMGN - MarketBeat
Corundum Group Inc. Grows Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Position Lifted by Precedent Wealth Partners LLC - MarketBeat
Franklin Street Advisors Inc. NC Sells 21,044 Shares of Amgen Inc. $AMGN - MarketBeat
The Technical Signals Behind (AMGN) That Institutions Follow - news.stocktradersdaily.com
Sen. Sheldon Whitehouse Sells Amgen Inc. (NASDAQ:AMGN) Stock - MarketBeat
Amgen (NASDAQ:AMGN) Upgraded to Buy at Wall Street Zen - MarketBeat
(AMGN) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
(AMGN) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Colorado Adopts First State Payment Cap for Amgen’s Enbrel (1) - Bloomberg Law News
Cramer's Stop Trading: Amgen - MSN
How (AMGN) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Long-term benefit of Amgen’s Repatha in reducing MACE shown in Phase III trial - Yahoo Finance
Greenwood Capital Associates LLC Sells 5,673 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Purchased by Mattern Capital Management LLC - MarketBeat
Hilltop National Bank Makes New Investment in Amgen Inc. $AMGN - MarketBeat
Amgen stock maintains Outperform rating at Oppenheimer after positive Repatha trial - Investing.com
Amgen Inc. $AMGN Stock Position Lifted by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Amgen (AMGN) Is Up 9.7% After Repatha Trial Success and Puerto Rico Expansion Announcement – What's Changed - simplywall.st
Amgen Inc. $AMGN Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Is Amgen Inc. (AMG0) stock a buy for dividend portfoliosJuly 2025 Chart Watch & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Amgen Inc. (AMG0) stock extend growth story2025 EndofYear Setup & Verified Chart Pattern Signals - newser.com
Will Amgen Inc. price bounce be sustainable2025 Biggest Moves & Smart Money Movement Tracker - newser.com
Why global investors buy Amgen Inc. (AMG0) stockPortfolio Update Report & Weekly Breakout Opportunity Watchlist - newser.com
What data driven models say about Amgen Inc.’s futureJuly 2025 Breakouts & Detailed Earnings Play Strategies - newser.com
Precision Trading with Amgen Inc. (AMGN) Risk Zones - news.stocktradersdaily.com
Short interest data insights for Amgen Inc.Weekly Profit Recap & AI Driven Price Forecasts - newser.com
Primary-Prevention Data Should Boost Uptake Of Amgen’s Repatha - insights.citeline.com
Responsive Playbooks and the AMGN Inflection - news.stocktradersdaily.com
These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap - Benzinga
Cartography Bio maps out cancer drug plan with $67 million from Pfizer, Amgen venture units and more - The Business Journals
Amgen Surges on Repatha Expansion, Manufacturing Boost, and Strong Earnings - FinancialContent
Amgen (AMGN): Examining Valuation After Recent 6% Share Price Rise - Yahoo Finance
Amgen claims ‘landmark’ study result that could widen heart drug’s use - BioPharma Dive
Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term - sharewise.com
(AMGN) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Amgen (AMGN) Hits Key Milestones with Repatha in Cardiovascular Trial - GuruFocus
Stocks making big moves yesterday: ZoomInfo, Dave, Atkore, Saia, and Amgen - The Globe and Mail
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.07%
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):